Health Care & Life Sciences » Pharmaceuticals | Guizhou Bailing Group Pharmaceutical Co. Ltd.

Guizhou Bailing Group Pharmaceutical Co. Ltd. | Income Statement

Fiscal year is January-December. All values CNY Millions.
2013
2014
2015
2016
2017
2018
Sales/Revenue
1,388
1,509
1,873
2,182
2,548
3,085
Cost of Goods Sold (COGS) incl. D&A
586
645
750
821
987
1,300
Gross Income
802
864
1,123
1,361
1,561
1,785
SG&A Expense
439
445
580
756
958
1,130
EBIT
357
398
493
593
602
654
Unusual Expense
-
-
12
-
-
-
Non Operating Income/Expense
5
4
14
3
36
7
Interest Expense
52
48
30
22
13
21
Pretax Income
326
377
492
580
632
651
Income Tax
53
62
76
94
100
94
Consolidated Net Income
273
315
416
486
532
572
Net Income
270
310
411
482
526
563
Net Income After Extraordinaries
270
310
411
482
526
563
Net Income Available to Common
270
310
411
482
526
563
EPS (Basic)
0.19
0.22
0.29
0.34
0.37
0.40
Basic Shares Outstanding
1,411
1,411
1,411
1,411
1,411
1,411
EPS (Diluted)
0.19
0.22
0.29
0.34
0.37
0.39
Diluted Shares Outstanding
1,411
1,411
1,411
1,411
1,411
1,444
EBITDA
406
463
566
673
675
735
Other Operating Expense
6
22
50
12
2
-
Non-Operating Interest Income
10
17
18
5
8
8
Minority Interest Expense
3
5
5
4
6
9

About Guizhou Bailing Group Pharmaceutical Co.

View Profile
Address
Xihang Avenue
Anshun Guizhou 561000
China
Employees -
Website http://www.gzbl.com
Updated 07/08/2019
Guizhou Bailing Group Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of Chinese medicines. It offers medicines in the form of tablets, capsules, syrups, soft capsules, granules, pills, powder, sprays, creams, and injections. Its products are used for treatment of cardiovascular and cerebrovascular diseases, cough, common cold, and fever.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.